Search results
Progress towards treatments for inherited retinal conditions continues to gather pace and there’s been lots going on in the last few months, with more and more approaches being explored. This round-up gives a flavour of the variety of developments, including plenty that are not specific to a particular genetic fault.
Tomasz Tomkiewicz is undertaking a PhD studentship funded by Retina UK and The Macular Society.
Jing Yu is a Research Assistant at the Nuffield Department of Clinical Neurosciences at the John Radcliffe Hospital in Oxford.
This session will introduce the technique of optogenetics and its potential for development into a treatment for IRDs.
Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.
These frequently asked questions should provide a response for most of the queries you might raise.
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.
Nurturing a new generation of scientists is a vital investment in the future of retinal disease research, so we are delighted to be funding, in collaboration with the Macular Society, a new PhD studentship at Oxford University, supervised by Professor Robert MacLaren.
Jenny Dewing is a postdoctoral researcher working on a Retina UK-funded project with Dr Arjuna Ratnayaka at the University of Southampton.
Simon spent 40 years as a consultant ophthalmic surgeon at the North Hampshire Hospital in Basingstoke.
